Encompass Health (US:EHC)2026-02-06 16:02Financial Data and Key Metrics Changes - In Q4 2025, revenue increased by 9.9% to $1.5 billion, while adjusted EBITDA rose by 15.9% to $335.6 million, driven by 5.3% discharge growth and a 4.1% increase in net revenue per discharge [14][16] - For the full year 2025, revenue grew by 10.5%, and EBITDA increased by 14.9%, with premium labor costs declining by over $21 million from 2024 [6][11] Business Line Data and Key Metrics Changes - The company added 517 beds in 2025, with 390 from new hospitals and 127 from existing hospitals, reflecting ongoing investments in capacity [7] - The full-year discharge to community rate was 84.6%, with discharge to acute care at 8.6% and discharge to skilled nursing facilities (SNF) at 6.1%, all favorable compared to industry averages [6][7] Market Data and Key Metrics Changes - The company experienced strong fee-for-service growth in Q4, although challenges were noted with Medicare Advantage, particularly with one national payer that saw a significant drop in conversion rates [26][27] - The Veterans Affairs (VA) program represented 19% of managed care volume, with a growth rate of 22% for the year, indicating strong performance in this segment [30] Company Strategy and Development Direction - The company plans to augment its capacity expansion strategy by introducing small format hospitals starting in 2027, which will support a hub and spoke strategy in larger markets [7][8] - The company is actively engaging with regulatory bodies to ensure compliance and mitigate risks associated with changes in the IRF industry, particularly regarding the RCD and TEAM models [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to adapt to regulatory changes and maintain growth, citing a strong demand for IRF services [10][11] - The initial guidance for 2026 includes net operating revenue of $6.365 billion to $6.465 billion and adjusted EBITDA of $1.34 billion to $1.38 billion, reflecting expectations for continued growth [17] Other Important Information - The company maintained a strong balance sheet with a year-end net financial leverage of 1.9x, allowing for flexibility in investments and shareholder distributions [11][16] - Significant investments were made in operations, including $158 million in share repurchases and over $70 million in cash dividends [11][16] Q&A Session Summary Question: Can you elaborate on volume trends and comp issues for 2026? - Management noted that Q4 faced challenging comps due to strong performance in the previous year, with new hospitals contributing to volume growth [20][21] Question: What is the payer mix and growth across different classes? - Fee-for-service growth was strong, but challenges were noted with Medicare Advantage, particularly with one payer that saw a drop in conversion rates [26][27] Question: How do pilot programs like TEAM typically play out? - Management indicated that past pilot programs have had mixed outcomes, with some being implemented nationally while others did not continue beyond the pilot phase [38][39] Question: What is the rationale behind adding small format hospitals? - The company aims to address market demand and capacity constraints with a new economically feasible model for smaller hospitals, enhancing service delivery in growing markets [90][91] Question: How is the company addressing malpractice concerns? - Management reported no significant changes in malpractice activity from 2024 to 2025, indicating stability in this area [85]